Clinical Trial Closeup

Edited by Emmett T. Cunningham Jr., MD, PhD

Closing the escape route of anti-VEGF-A

By suppressing VEGF-C and -D, OPT-302 shows potential to improve outcomes in nAMD with existing therapies.

Modulating macrophages to target GA

Investigational candidate aims to change macrophage behavior in management of dry age-related macular degeneration.

Wet AMD gene therapy shows promise

Phase I/IIa results of RGX-314 confirm protein uptake over months.

What’s Next for Bispecific Antibody Faricimab

With the Phase II BOULEVARD trial completed, this dual-action, single-molecule agent for DME heads into Phase III trials.

A Deeper Dive Into Abicipar Trials

Answers about vision outcomes, inflammation and where it fits in the treatment armamentarium.

A Smaller, Faster Anti-VEGF Therapy

How brolucizumab may extend dosing out to 12 weeks.

Moving the Needle on Ocular Cancer

How AU-011 selectively targets melanoma without damaging nearby ocular tissue.

A Drop for DME and AMD

Are clinical investigators close to finding the Holy Grail for retinal disease?

Restoring Cell Function to Block VEGF

Integrin peptide therapy Luminate shows potential of extending DME treatment.

FA Insert Delivers At 12 Months

Top-line results through 12 months show sustained effect of three-year insert for noninfectious posterior uveitis.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.